Charles Wagner - Vertex Pharmaceuticals CFO, Executive Vice President
| VRTX Stock | USD 503.20 6.98 1.37% |
President
Mr. Charles F. Wagner was appointed as Chief Financial Officer, Executive Vice President of the company. Effective April 10, 2019 since 2019.
| Age | 57 |
| Tenure | 6 years |
| Professional Marks | MBA |
| Address | 50 Northern Avenue, Boston, MA, United States, 02210 |
| Phone | 617 341 6100 |
| Web | https://www.vrtx.com |
Charles Wagner Latest Insider Activity
Tracking and analyzing the buying and selling activities of Charles Wagner against Vertex Pharmaceuticals stock is an integral part of due diligence when investing in Vertex Pharmaceuticals. Charles Wagner insider activity provides valuable insight into whether Vertex Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Vertex Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Vertex Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Charles Wagner over a year ago Sale by Charles Wagner of 3000 shares of Vertex Pharmaceuticals | ||
Charles Wagner over a year ago Payment of 2707 shares by Charles Wagner of Vertex Pharmaceuticals subject to Rule 16b-3 |
Vertex Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.1268 % which means that it generated a profit of $0.1268 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0315) %, meaning that it created substantial loss on money invested by shareholders. Vertex Pharmaceuticals' management efficiency ratios could be used to measure how well Vertex Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.03 in 2025. Return On Capital Employed is likely to drop to -0.01 in 2025. At this time, Vertex Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 13.6 B in 2025, whereas Intangible Assets are likely to drop slightly above 454.9 M in 2025.Similar Executives
| Found 11 records | PRESIDENT Age | ||
| Kelley Boucher | Alnylam Pharmaceuticals | N/A | |
| Joseph LaRosa | Regeneron Pharmaceuticals | 65 | |
| Christopher Fenimore | Regeneron Pharmaceuticals | 53 | |
| Laura SeppLorenzino | Intellia Therapeutics | 63 | |
| Marion McCourt | Regeneron Pharmaceuticals | 64 | |
| Andrew JD | Verve Therapeutics | 58 | |
| Edward III | Intellia Therapeutics | 48 | |
| Suma Krishnan | Krystal Biotech | 60 | |
| Daniel Plew | Regeneron Pharmaceuticals | 52 | |
| Gregory Zante | Viking Therapeutics | 53 | |
| Kevin Fitzgerald | Alnylam Pharmaceuticals | 57 | |
Management Performance
| Return On Equity | -0.0315 | ||||
| Return On Asset | 0.13 |
Vertex Pharmaceuticals Leadership Team
Elected by the shareholders, the Vertex Pharmaceuticals' board of directors comprises two types of representatives: Vertex Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vertex. The board's role is to monitor Vertex Pharmaceuticals' management team and ensure that shareholders' interests are well served. Vertex Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vertex Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jonathan JD, Executive Officer | ||
| Stephanie Franklin, Senior Officer | ||
| Mike Tirozzi, SVP Officer | ||
| Damian Esq, Chief VP | ||
| Charles Wagner, CFO, Executive Vice President | ||
| Jeffrey MD, Executive Chairman | ||
| Ourania Tatsis, Ex Officer | ||
| Nina Devlin, Senior Officer | ||
| Amit JD, Executive Officer | ||
| MD FASN, President CEO | ||
| Susie Lisa, Senior Relations | ||
| Stuart BSc, Executive COO | ||
| Kristen CPA, Senior Officer | ||
| Susie CFA, Senior Relations | ||
| Kristen Ambrose, Tax, Accounting |
Vertex Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vertex Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0315 | ||||
| Return On Asset | 0.13 | ||||
| Profit Margin | (0.05) % | ||||
| Operating Margin | 0.45 % | ||||
| Current Valuation | 126.64 B | ||||
| Shares Outstanding | 256.79 M | ||||
| Shares Owned By Insiders | 0.11 % | ||||
| Shares Owned By Institutions | 96.65 % | ||||
| Number Of Shares Shorted | 5.07 M | ||||
| Price To Earning | 24.57 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Vertex Stock Analysis
When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.